Short answer:
There isn’t a biosimilar for Tepezza (teprotumumab‑trbw) that’s approved for the same indication, so you can’t directly compare “Tepezza vs. an approved biosimilar.” The only alternative treatments that are actually available for thyroid‑eye disease (TED) are non‑biologic options—systemic corticosteroids, radiation, surgery, or off‑label drugs like tofacitinib—but none of those are biologic “biosimilars” of Tepezza.
If you’re looking at value, the comparison is really between Tepezza and those other, non‑biologic therapies. Below is a quick rundown of the options and the factors that influence “value” from a cost‑effectiveness standpoint.
1. What Tepezza is and why it’s expensive
| Feature |
Details |
| Mechanism |
Human monoclonal antibody that blocks IGF‑1R, dampening the autoimmune inflammation that drives TED. |
| Dosing |
10 mg/kg IV every 3 weeks × 7 doses (≈ 24 weeks). |
| Price |
About $100,000–$120,000 per course in the U.S. (price varies by payer, discounts, and patient assistance programs). |
| Evidence |
Phase 3 trials showed >70 % of patients had a clinically meaningful reduction in proptosis and diplopia versus ~10 % with placebo. |
| Safety |
Common: hyperglycemia, infusion reactions, muscle spasms. Rare: anaphylaxis, ocular inflammation. |
Because Tepezza is the only drug that has been approved by the FDA for TED, its price reflects the cost of bringing a new biologic to market and the relatively small patient population (≈ 10,000–20,000 people in the U.S. with active, moderate‑to‑severe TED).
2. What’s on the “biosimilar” side of the spectrum
Biosimilars are follow‑on biologics that are highly similar to an already approved reference biologic. For TED there are no biosimilars—the FDA has only approved Tepezza for this indication. If you’re considering a biologic alternative for TED (e.g., a monoclonal antibody that blocks a different target), you’ll find that none of those drugs have a “biosimilar” version that’s approved for TED.
There are, however, biosimilars for drugs used in other eye conditions (e.g., biosimilars of ranibizumab for age‑related macular degeneration) or for other autoimmune diseases (e.g., adalimumab biosimilars). Those drugs are not interchangeable with Tepezza for TED.
3. Alternative, non‑biologic treatments (the real “compare‑with” group)
| Treatment |
Typical cost (annual) |
Evidence level |
Typical outcomes |
Key pros |
Key cons |
| Systemic corticosteroids |
$300–$3,000 (oral or IV) |
Moderate (small trials, real‑world data) |
30–60 % improvement in proptosis/diplopia |
Cheap, widely available |
High risk of systemic side effects, relapse on taper |
| Radiation |
$3,000–$10,000 |
Low‑to‑moderate |
30–50 % improvement |
Useful for refractory cases |
Radiation risks, long‑term complications |
| Surgical decompression |
$5,000–$10,000 |
Low (case series) |
Variable improvement |
Rapid symptom relief |
Surgical morbidity, not curative |
| Tofacitinib (JAK inhibitor, off‑label) |
$30,000–$40,000 per year |
Emerging (case reports, small studies) |
50–70 % response in select patients |
Oral, rapid onset |
Immunosuppression, cost, not FDA‑approved for TED |
Bottom line: In terms of directly comparable biologic options, there simply aren’t any. If your goal is to assess value, you have to weigh the high cost of Tepezza against the modest efficacy of the other treatments and the additional costs of monitoring and managing side effects.
4. How to decide on the “best value” option
| Decision factor |
What to consider |
| Severity and activity of TED |
Tepezza is FDA‑approved for moderate‑to‑severe TED with active inflammation (e.g., proptosis > 20 mm, diplopia, optic neuropathy). For mild or inactive disease, watchful waiting or low‑dose steroids may be sufficient. |
| Insurance coverage & reimbursement |
Many commercial insurers cover Tepezza under prior‑authorization, but the cost to the patient can be substantial. Check for patient assistance programs (Tepezza Care) that can reduce copays. |
| Risk tolerance |
If you’re comfortable with a high upfront cost for a strong evidence base, Tepezza is likely the best value clinically. If you want to avoid high out‑of‑pocket expenses and are okay with a less robust response, consider steroids or surgery. |
| Comorbidities |
Patients with uncontrolled diabetes, immunosuppression, or a history of severe steroid reactions may be at higher risk for complications from Tepezza or steroids, respectively. |
| Timing |
Tepezza requires 7 infusions over 24 weeks. Some patients prefer a shorter course or an oral medication. |
5. Quick decision aid
-
Is the TED moderate‑to‑severe with active inflammation?
- Yes → Tepezza (highest efficacy, high cost).
- No → Consider steroids or surgery.
-
Do you have insurance that covers Tepezza?
- Yes → Confirm copay amounts, check for patient assistance.
- No → Explore alternative therapies or negotiate with the pharmacy.
-
Are you concerned about cost?
- High concern → Check for Tepezza Care or other discount programs; evaluate steroid or surgical options.
- Low concern → Tepezza offers the best evidence‑based benefit.
6. Bottom line for your question
- No approved biosimilar for Tepezza → you cannot compare them directly.
- Value assessment should be made against the other, less expensive options (steroids, radiation, surgery) or off‑label agents.
- Tepezza provides the best evidence for efficacy but is the most expensive option.
- Biosimilars are relevant only for drugs that have a reference biologic already approved for a different indication—none exist for TED yet.
If you have specific insurance details or a particular biosimilar in mind, let me know and we can drill into the numbers further!